Enliven Therapeutics (NASDAQ:ELVN) Reaches New 52-Week High at $26.20

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares reached a new 52-week high during trading on Friday . The stock traded as high as $26.20 and last traded at $26.05, with a volume of 50210 shares. The stock had previously closed at $25.02.

Wall Street Analyst Weigh In

Several research analysts have commented on ELVN shares. Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Mizuho started coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price objective on the stock. Finally, Robert W. Baird started coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price objective on the stock.

Enliven Therapeutics Trading Up 6.1 %

The firm has a fifty day simple moving average of $22.53 and a 200 day simple moving average of $19.02.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. As a group, equities analysts predict that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction on Monday, April 29th. The stock was sold at an average price of $16.97, for a total value of $55,152.50. The sale was disclosed in a filing with the SEC, which is available through this link. In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $23.18, for a total transaction of $278,160.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $16.97, for a total value of $55,152.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,142,148 shares of company stock worth $25,390,954. 29.20% of the stock is currently owned by company insiders.

Institutional Trading of Enliven Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AJOVista LLC acquired a new stake in Enliven Therapeutics during the 4th quarter worth about $28,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Enliven Therapeutics in the 4th quarter valued at about $66,000. EntryPoint Capital LLC purchased a new position in shares of Enliven Therapeutics in the 1st quarter valued at about $167,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after purchasing an additional 1,029 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of Enliven Therapeutics by 17.8% in the 4th quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after purchasing an additional 2,041 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.